Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343811 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment
A Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT00343811 is a Phase 3 study of Attention Deficit Hyperactivity Disorder that has completed, run by Cephalon. The registered enrollment target is 120 participants, below the 205-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00343811, a Phase 3 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment.
Conditions Studied
Interventions
- DRUG Modafinil
Study Locations (20)
California
- UCI Child Development Center - Irvine
- University of California at San Francisco - San Francisco
- Encompass Clinical Research - Spring Valley
Florida
- Sarkis Family Psychiatry - Gainesville
- Amedica Research Institute, Inc. - Hialeah
- Miami Research Associates - Miami
Kentucky
- Kentucky Pediatric/Adult Research - Bardstown
- Michael J. Rieser, MD, PSC - Lexington
- Four Rivers Clinical Research, Inc. - Paducah
North Carolina
- Piedmont Neuropsychiatry - Charlotte
- Triangle Neuropsychiatry - Durham
Arkansas
- Clinical Study Centers, LLC - Little Rock
Colorado
- Alpine Clinical Research - Boulder
Georgia
- Child Neurology Associates - Atlanta
Michigan
- Clinical Neurophysiology Services - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343811
The ClinicalTrials.gov registry entry for NCT00343811 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (41% lower). The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Modafinil is the first listed.
NCT00343811 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00343811 about?
NCT00343811 is a clinical study titled "Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment". The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment.
What is the current status of trial NCT00343811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2006-06. Estimated completion is 2006-09.
What conditions does trial NCT00343811 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00343811?
The interventions under investigation include: Modafinil (DRUG).
Who is sponsoring clinical trial NCT00343811?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00343811 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
COMPLETED · Phase 3
-
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
COMPLETED · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
-
A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.